COMP <GO>
COO vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
The Cooper Companies Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: COO 6
— ABBV 9
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: COO
LAST: $59.55 (-1.31%) • MKT CAP: $11.47B
options-implied-move
6.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.50% | 70.20% | -4.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.30% | 29.00% | -23.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.3x | 33.3x | -20.00 | COO | /valuation <GO> |
| Free Cash Flow Yield | 3.78% | 3.47% | +0.31 | COO | /fcf-yield <GO> |
| Operating Margin | 16.70% | 24.60% | -7.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 9.20% | 6.90% | +2.30 | COO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 8.60% | -3.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 5.33 | -2.20 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | COO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 7.40% | -0.50 | COO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 72.8 | -20.26 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.15 | -0.14 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.5x | 113.1x | -84.60 | COO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.47B | $513.86B | -$502.39B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COO REV | ABBV REV | COO GROSS % | ABBV GROSS % | COO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.09B | $61.16B | 65.5% | 70.2% | $433.7M | $17.82B |
| FY 2024 | $3.90B | $56.33B | 66.6% | 70.0% | $288.1M | $17.83B |
| FY 2023 | $3.59B | $54.32B | 44.0% | 44.0% | $445.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COO // BETA 1.01
ABBV // BETA 1.15